Biomind Labs Inc.
BMND
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -55.84% | -427.51% | -197.97% | 45.07% | 64.12% |
| Total Depreciation and Amortization | -- | -100.00% | -100.00% | -100.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 149.38% | 271.50% | 128.01% | -76.81% | -164.11% |
| Change in Net Operating Assets | -87.39% | 1,164.44% | 315.63% | 38.18% | 1,720.00% |
| Cash from Operations | -13,300.00% | 52.29% | 65.17% | 178.17% | 100.43% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -75.21% | 16.49% | -99.48% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -75.21% | 28.21% | -99.48% | -- |
| Foreign Exchange rate Adjustments | 1,980.00% | -208.75% | -72.73% | 6.13% | -112.82% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -267.00% | 258.01% | 100.75% | -100.00% |